HDL Therapeutics today announced a merger agreement with Swiftmerge Acquisition at a valuation of $480 milion for the combined company.
The target is a commercial stage biotech company with an FDA-approved cardiovascular therapy the Plasma Delipidation System (PDS-2
System) for reducing coronary atheroma in patients with homozygous familial hypercholesterolemia. Cholesterol and calcium deposits are the common culprits behind this arterial condition.
Investors in HDL Therapeutics will receive a combination of cash and equity in Swiftmerge totalling $400 million, subject to adjustments.
The combined company itself would receive approximately $104 million in gross proceeds, including $24 million of cash held in Swiftmerge’s trust account (assuming no redemptions) and approximately $80 million in new pipe financing that Swiftmerge seeks to raise.
Swiftmerge in a June said shareholders redeemed 20,553,090 shares at $10.39 each ahead of an extension vote. The measure pushed the SPAC’s completion deadline from June 17 to March 15, 2024.
The SPAC had held about $225 million in trust as of April, when Swiftmerge signed an LOI with HDL. Based on that amount, redemptions erased about 89% of the trust two months ago.
Swiftmerge raised $200 million in a December 2021 ipo “to pursue opportunities targeting disruptive consumer companies utilizing technology and the internet to evolve the way that consumers interact with the market.” Read more.
Source: HDL Therapeutics Combining with Swiftmerge Acquisition in 0M Deal
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Automotive / EVs, Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- ChartPrime. Elevate your Trading Game with ChartPrime. Access Here.
- BlockOffsets. Modernizing Environmental Offset Ownership. Access Here.
- Source: https://spacfeed.com/hdl-therapeutics-combining-with-swiftmerge-acquisition-in-480m-deal
- :is
- $400 Million
- 15%
- 17
- 20
- 2021
- 2024
- 39
- a
- About
- Account
- acquisition
- adjustments
- ago
- Agreement
- ahead
- amount
- an
- and
- announced
- approximately
- April
- ARE
- AS
- At
- based
- behind
- biotech
- Cash
- combination
- combined
- combining
- commercial
- Common
- Companies
- company
- completion
- condition
- consumer
- Consumers
- deal
- December
- december 2021
- deposits
- disruptive
- each
- equity
- Ether (ETH)
- evolve
- extension
- financing
- For
- from
- gross
- had
- Held
- HTTPS
- image
- in
- Including
- interact
- Internet
- IPO
- itself
- june
- March
- Market
- measure
- Merger
- million
- months
- more
- New
- no
- of
- on
- opportunities
- patients
- pipe
- Plasma
- plato
- Plato Data Intelligence
- PlatoData
- Posts
- proceeds
- pursue
- pushed
- raise
- raised
- Read
- receive
- redemptions
- reducing
- s
- Said
- Seeks
- Shareholders
- Shares
- signed
- SPAC
- Stage
- subject
- system
- TAG
- Target
- targeting
- Technology
- that
- The
- therapeutics
- therapy
- this
- to
- today
- Trust
- two
- Utilizing
- Valuation
- Vote
- Way..
- when
- will
- with
- would
- zephyrnet